Roivant PHocus Analyst Chorus Continues Into the Weekend: Leerink Flags Up to $10 Billion Peak Sales Potential for Mosliciguat Across Multiple Pulmonary Hypertension Indications
Roivant Sciences (NASDAQ: ROIV) analyst commentary continued through the weekend following Tuesday's Pulmovant Phase 2 PHocus mosliciguat win, with Leerink Partners' David Risinger flagging up to $10 billion peak sales potential for mosliciguat across multiple pulmonary hypertension indications. The Leerink estimate substantially exceeds the ~$3 billion PH-ILD-only estimate Guggenheim disclosed Wednesday September 9. Other analyst peak sales projections ranged from $1.5 billion to $5 billion depending on indication assumptions and market-share methodology. The week's analyst upgrade sequence: Jefferies to $52 (from $42), Guggenheim to $46 (from $42), Piper Sandler to $55 (from $40), TD Cowen to $55 (from $50), BofA also raised. Consensus 12-month price target clusters around $50-55. The PHocus trial produced a 56.3% placebo-adjusted PVR reduction at Week 16 (p<0.0001), 6MWD +35.2 meters, and NT-proBNP −357.7 pg/mL (−53.2%). The Phase 3 PHrontier trial in approximately 375 patients is enrolling. Mosliciguat's mechanism (inhaled soluble guanylate cyclase activator working independently of heme and nitric oxide) differentiates it from sGC stimulators like Bayer's Adempas (riociguat) and prostacyclin analogs like United Therapeutics' Tyvaso (treprostinil).